High Incidence of Human Papillomavirus Types 16 and 18 in Cervical Carcinoma Patients in a Tertiary Care Unit, Jabalpur, MP, India
- 17 Downloads
Cervical cancer is the second leading cause of deaths due to cancer, among Indian women. Persistent infection of high-risk genotypes of human papillomavirus (HPV) is the leading cause of cervical cancer. The aim of the study was to estimate the incidence of HPV 16 and 18 infections in cervical cancer patients from Jabalpur, Madhya Pradesh, India.
Materials and Methods
In this hospital-based study, cervical biopsy samples, received from tertiary healthcare hospital, were subjected to molecular tests for HPV 16 and HPV 18. The p53 polymorphism at the 72 position was studied by PCR. The clinical and sociodemographic information of the patients was analyzed using SPSS 20.
A total of 87 cervical carcinoma tissues were analyzed by type-specific PCR for its presence. Forty-five (51.7%) were infected with HPV 16, and 27 (31%) had HPV 18. Coinfection of HPV 16 and HPV 18 was detected in 15 (17.2%) patients. The overall HPV incidence was 65.5% (n = 57). Arginine (Arg) homozygosity dominance was not significant among cervical carcinoma patients. Illiteracy was significantly associated with HPV incidence.
The findings indicate HPV 16 and HPV 18 are the major causes of cervical carcinoma in Central India. HPV 16 was more prominent infection than HPV 18. Arg homozygosity at the 72 position in p53 gene was not associated with cervical carcinoma. A community-based study will be useful to establish the prevalence of HPV, which will help in interventions such as vaccination in the area.
KeywordsCervical carcinoma High-risk genotypes Human papillomavirus India Madhya Pradesh
The authors are grateful to the Secretary to the Government of India, DHR, MoH and FW, and the Director General, ICMR, for funding under establishment of grade II virology laboratory (Grant No. VIR/43/2011-ECD-I). The authors thank Dr. Aparup Das, Director, ICMR-NIRTH, Jabalpur, for providing PCR kits as intramural support and encouragement during the study. Authors are thankful to Dr. Ravindra Kumar, Scientist B, and ICMR-NIRTH for critical comments on MS. The manuscript has been approved by the publication screening committee of ICMR-NIRTH, Jabalpur, and assigned with the number ICMR-NIRTH/PSC/08/2019.
Compliance with Ethical Standards
Conflict of interest
The authors declare that there is no conflict of interest.
- 1.WHO, Human-papillomavirus and Cervical Cancer. 2019. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. Accessed 24 Jan 2014.
- 2.WHO Immunization, Vaccines and Biologicals. 2018. https://www.who.int/immunization/diseases/hpv/en/. Accessed Mar 2018.
- 9.Genital HPV Infection—Fact Sheet. https://www.cdc.gov/std/hpv/stdfact-hpv.htm. Accessed 16 Nov 2017.
- 14.ICO Information Centre on HPV and cancer (Summary Report 2014-08-22). Human Papillomavirus and Related Diseases in India. 2014.Google Scholar
- 24.Halperin EC, Wazer DE, et al. Principal and practice of radiation oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.Google Scholar
- 31.Ojiyi EC, Dike EI, Nzewuihe AC, Ejikem EC. Epidemiology of cervical cancer at the Anambra State University Teaching Hospital, Awka. Trop J Med Sci. 2012;1:10–3.Google Scholar
- 32.Katiyar S, Thelma BK, Murthy NS, et al. Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem. 2003;252:117–24.Google Scholar
- 33.Singh N. HPV and cervical cancer-prospects for prevention through vaccination. Indian J Med Paediatr Oncol. 2005;2005(26):20–3.Google Scholar